Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

Bookmark and Share
Published: 16 Mar 2023
Views: 37
Rating:
Save
Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Renu Eapen speaks to ecancer about her talk at EAU 2023 regarding the LuTectomy study.

LuTectomy is a prospective study of dosimetry, safety and potential benefit of upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with high-risk localised prostate cancer.

She discusses the background and results of the study.

Dr Eapen talks about how this can be game changing for the treatment of patients with high-risk localised prostate cancer.